- Fuller 1989 and the Definition That Built an Industry
- Suez et al. 2018: Probiotics Delay Post-Antibiotic Microbiome Recovery
- Zmora et al. 2018: Colonization Is Individual, Not Universal
- AGA 2020 Clinical Practice Guidelines: The Three Conditions
- Kristensen et al. 2016: No Microbiome Changes in Healthy Adults
- Ford et al. 2018 and the IBS Meta-Analysis Landscape
Fuller 1989 and the Definition That Built an Industry
The modern probiotic concept traces to a 1989 paper by Roy Fuller in the Journal of Applied Bacteriology, which defined probiotics as "live microbial feed supplements which beneficially affect the host animal by improving its intestinal microbial balance." This definition — deceptively simple, with "beneficially affect" doing enormous work — established the conceptual framework that the subsequent $80 billion market was built on. The underlying assumption is that the microbiome has a "correct" balance; that commercial bacterial strains can shift it; and that shifting it produces health benefits. All three of these assumptions are empirically contested in 2026 to a degree the 1989 definition could not anticipate.
Fuller's definition was applied primarily to animal husbandry, where probiotic supplementation of livestock had demonstrated production benefits. The extrapolation to human health was commercially motivated and scientifically premature. The specific Lactobacillus and Bifidobacterium strains used in early animal probiotic products were adopted into human supplements with minimal clinical validation for human-relevant outcomes. The regulatory environment allowed this: in the United States, most probiotic supplements are classified as dietary supplements under the Dietary Supplement Health and Education Act of 1994, meaning they require no demonstration of efficacy before marketing. A manufacturer can sell a probiotic for "digestive health" without evidence that it produces any digestive health benefit, as long as the claim avoids diagnosing, treating, or curing a disease.
The consequence is a product category with decades of sales history, enormous consumer investment, and a clinical evidence base that substantially fails to support the broad benefit claims the market implies. The distinction between "probiotics that have clinical evidence for specific conditions" — a relatively small set of strain-indication pairs — and "probiotics as a general category for general wellness" — the marketing premise — is the central evidentiary problem in this field.
Suez et al. 2018: Probiotics Delay Post-Antibiotic Microbiome Recovery
In September 2018, Eran Segal, Eran Elinav, and colleagues at the Weizmann Institute of Science published two papers in Cell that constituted the most significant challenge to the conventional probiotic narrative in decades. The first, by Suez et al., examined a question that appears obvious in retrospect: do probiotics actually help the gut microbiome recover after antibiotic treatment? The standard advice — take probiotics during and after antibiotic courses to restore gut flora — had been disseminated by physicians and pharmacists for years without rigorous evidence.
Suez et al. randomized 21 participants to receive either a standard 11-strain probiotic supplement (containing Lactobacillus and Bifidobacterium species at doses typical of commercial products), no intervention, or autologous fecal microbiota transplant (FMT) — a transplant of each participant's own pre-antibiotic stool. The probiotic group showed complete reconstitution of the supplemented strains in the gastrointestinal tract — by that measure, the supplement "worked." However, the recovery of the participants' native gut microbiome — the indigenous bacterial communities that existed before antibiotic treatment — was significantly delayed in the probiotic group compared to both the control group and the FMT group. At five months of follow-up, the probiotic group's native microbiome had not fully recovered to pre-antibiotic composition; the no-intervention control group recovered within weeks; the FMT group recovered within days.
The mechanism proposed by Suez et al. is that the supplemented probiotic strains colonized the gut niche and occupied ecological space that would otherwise have been recolonized by the returning native bacteria. The probiotic bacteria did not die — they established. But their establishment suppressed the return of the indigenous microbiome that the intervention was intended to support. This is the opposite of the marketed benefit. The supplement industry's response largely focused on the small sample size (21 participants) and the single probiotic formulation tested. The directional finding — that probiotics may not facilitate and may actively impede post-antibiotic gut recovery — has not been comprehensively refuted by subsequent larger trials.
Zmora et al. 2018: Colonization Is Individual, Not Universal
The second 2018 Cell paper, by Zmora et al. from the same Weizmann group, addressed a more fundamental question: do commercial probiotic strains actually colonize the gut of the people taking them? The universal assumption underlying probiotic marketing is that bacteria in a capsule transit to the gastrointestinal tract and establish residence, where they exert beneficial effects. Zmora et al. tested this directly in 25 volunteers who underwent upper endoscopy and colonoscopy before and after taking the same 11-strain probiotic supplement used in the Suez study.
The findings were striking. Colonization was not universal. Participants fell into two distinct groups: "permissive" individuals, in whom the probiotic strains successfully colonized multiple gut regions and persisted through the supplementation period, and "resistant" individuals, in whom the strains were detected briefly after ingestion but failed to establish in the gastrointestinal mucosa. Importantly, fecal analysis — the standard method used in clinical trials and commercial microbiome testing — did not accurately predict colonization status. A participant whose stool samples showed the probiotic strains might have had mucosal colonization or might have simply been passing the bacteria through without retention. This distinction matters enormously for interpreting the clinical trial literature, which overwhelmingly uses stool analysis rather than endoscopy to assess probiotic outcomes.
The Zmora findings suggest that strain-specific probiotics work for some people and not others, that there is currently no inexpensive clinical method to determine in advance which category a given patient falls into, and that the trial evidence for probiotic efficacy may be diluted by including non-colonizers in the study population. The clinical implications are not uniformly negative — they are precision medicine implications: the right probiotic for the right patient. But they directly undermine the "take probiotics for gut health" universal recommendation that the market is built on.
AGA 2020 Clinical Practice Guidelines: The Three Conditions
The American Gastroenterological Association published clinical practice guidelines on probiotic use in 2020 in Gastroenterology, representing the most rigorous systematic assessment of probiotic evidence by a major gastroenterological body. The guidelines panel — using the GRADE methodology to evaluate evidence quality and strength of recommendations — reached conclusions substantially more restrictive than commercial probiotic marketing would suggest.
The AGA recommends probiotics (with conditional or strong recommendations depending on the specific strain-indication pair) for three conditions: prevention of Clostridioides difficile (C. diff) infection in patients on antibiotic therapy, prevention of necrotizing enterocolitis in preterm infants, and treatment of pouchitis (inflammation of the surgically-created ileal pouch in patients who have had ulcerative colitis surgery). For all other conditions evaluated — Crohn's disease, ulcerative colitis outside the pouchitis indication, irritable bowel syndrome, antibiotic-associated diarrhea in non-C. diff context, and liver disease — the AGA found insufficient evidence to recommend probiotics and explicitly recommended against routine use in clinical practice outside of research settings.
The IBS finding requires particular attention because "probiotics for IBS" is one of the most commercially prominent claims in the probiotic market. The AGA's systematic review found that while some individual strains showed statistically significant improvements in composite IBS symptom scores in some trials, the evidence quality was low, effect sizes were modest, and results were not consistent across strains or trials. The panel concluded that the evidence was insufficient to recommend probiotics for IBS as a practice, even while acknowledging that specific strains might show benefit in future higher-quality trials. The gap between "some trials show modest symptom improvement for some strains" and "probiotics are widely marketed for IBS with strong implied efficacy claims" is not a scientific nuance — it is a fundamental misrepresentation of the evidence state.
Kristensen et al. 2016: No Microbiome Changes in Healthy Adults
Kristensen and colleagues published a systematic review in Genome Medicine in 2016 analyzing all available randomized controlled trials that had used 16S rRNA gene sequencing to assess whether probiotic supplementation changed the composition of the fecal microbiota in healthy adults. They identified seven eligible trials. The consistent finding across these trials: probiotics did not significantly change the overall composition of the gut microbiome in healthy participants.
This finding is often described as a negative result, but its implication cuts deeper than "probiotics don't work." The mechanism by which probiotics are supposed to benefit healthy people is by improving their microbiome — increasing diversity, shifting bacterial ratios toward health-associated compositions, reducing pathobiont abundance. If the microbiome does not measurably change with probiotic supplementation, the proposed mechanism cannot operate. Either the bacteria don't colonize, or they colonize transiently without changing the resident community, or the fecal measurement methodology misses mucosal changes. The Zmora findings suggest the third possibility is relevant, but they do not eliminate the first two as common outcomes.
The Kristensen result applies specifically to healthy adults — a population in whom beneficial microbiome shifts might be harder to demonstrate because healthy microbiomes have limited room for improvement. The probiotic literature in specific clinical populations with disrupted microbiomes (post-antibiotic, post-surgical, IBD) shows more heterogeneous results. But a substantial share of probiotic marketing and consumer use is directed at healthy adults for general wellness maintenance — precisely the population in whom the evidence of microbiome change is essentially absent.
Ford et al. 2018 and the IBS Meta-Analysis Landscape
A 2018 meta-analysis by Ford and colleagues in the American Journal of Gastroenterology analyzed 53 randomized controlled trials of probiotics in IBS and found a statistically significant improvement in composite IBS symptom scores (risk ratio for persistent symptoms 0.79, 95% CI 0.70–0.89). This finding is frequently cited as evidence that probiotics work for IBS. Several qualifications limit its interpretation.
First, the benefit was for the probiotic category as a whole — pooled across dozens of different strains, doses, and formulations. Meta-analyses that pool heterogeneous interventions can produce statistically significant pooled results while individual treatments have inconsistent or null effects. When Ford's analysis examined specific strain-indication pairs rather than the aggregate category, the evidence for any individual commercially available probiotic product was substantially thinner. Second, the absolute effect sizes were modest — a reduction in the proportion of patients with persistent symptoms from roughly 67% to 53%, roughly equivalent to other interventions for IBS that are not specifically promoted. Third, the quality of evidence was rated low to moderate by the authors themselves, reflecting heterogeneity across trials, inconsistency in outcomes measured, and risk of bias in many individual studies. The AGA guidelines, which used the Ford-type literature as an input, reached the "insufficient evidence" conclusion despite this pooled meta-analysis. The difference in conclusion is a difference in evidentiary standards, not a factual disagreement.